3 December 2022 - The most widely prescribed anti-viral drug in Australia, molnupiravir, should no longer be routinely given for the treatment of COVID-19, the national body that sets clinical medical guidelines has advised.

The new advice from the National Clinical Evidence Taskforce challenges Australia’s regimen of treatment for Covid-19, with molnupiravir currently prescribed by many GPs as a first choice treatment to eligible patients due to its suitability for most people. Another anti-viral, Paxlovid, is recognised as being more efficacious but is unsuitable for many people due to its large range of drug interactions.

Read The Australian article